With a better upfront offer on the table, enough bluebird bio investors have tendered their shares for the company's sale to ...

Shares of bluebird bio, Inc. (NASDAQ:BLUE) soared 50% in pre-market trading on Wednesday after the biotech firm revealed a ...

Investment firms The Carlyle Group Inc. (NASDAQ:CG) and SK Capital Partners, together with Beacon Parent Holdings, L.P., have ...

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today confirmed it has received an unsolicited non-binding written proposal (the “Ayrmid Proposal”) from Ayrmid Ltd (“Ayrmid”) to acquire ...

Joshua Cohen is a Boston-based writer who covers health policy. Bluebird bio is a highly innovative biotechnology company which develops gene therapies for several rare genetic disorders and cancers.

bluebird bio faces imminent bankruptcy unless a deal closes; current offer is $5 cash or $3 plus a low-value CVR. A rival ...

Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time as a ...

After bluebird bio acknowledged troubles keeping its business operational, the gene therapy biotech is launching a restructuring that will reduce the size of its workforce by about 25%.

Bluebird Bio has received a competing bid from Ayrmid to buy the cash-strapped gene-therapy company in a deal potentially valued at up to $110.5 million. Bluebird said late Friday that Ayrmid made ...

Gene therapy company Bluebird Bio on Tuesday announced a 25% reduction of its workforce as part of a restructuring meant to save money as it seeks to market its expensive but potentially life ...

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the restatement of its consolidated financial statements for the year ended December 31 ...